Roche aims for cancer test to target Tarceva; Diabetes to cost U.S. $3.35T by 2020;

@FiercePharma: Merck's Vytorin aids kidney patients, trial shows. Story | Follow @FiercePharma

> Roche has obtained a global license from U.S. biotech group Genzyme to develop a test for lung cancer cell mutations as a way to better target treatment with its drug Tarceva. Report

Special Report: Big Pharma's Top 5 Emerging Market Deals. Report

> More than half of Americans will have diabetes or be prediabetic by 2020 at a cost to the U.S. health care system of $3.35 trillion if current trends go on unabated, according to analysis of a new report from UnitedHealth. News

> PhRMA spent $5.2 million on lobbying expenses in the third quarter as it sought to influence the U.S. government on healthcare legislation, drug reimportation and other issues. Article

> The Generic Pharmaceutical Association spent around $373,000 in the third quarter on lobbying Congress and federal agencies about implementing healthcare reform and other issues. Story

Special Report: Big Pharma behaving badly: A timeline of settlements. Report 

> GW Pharmaceuticals' profits rose sharply following the successful launch of its cannabis-derived drug Sativex in Britain, and it said it had started final-stage trials of the medicine to treat cancer pain. Item

> Any increase in Ireland's corporation tax rate as part of a financial bailout could hurt the country's rapidly expanding pharmaceutical industry, currently its largest contributor to corporation tax. Report

> Pfizer said it has extended the expiration date of its tender offer to acquire King Pharmaceuticals for $14.25 per share until December 17. Article

Biotech News

 @FierceBiotech: Biotech's Biggest Spenders 2010. Report | Follow @FierceBiotech

 @JohnCFierce: Proving yet again how hot antibody tech is, boehringer agrees to $1.7B (provided all the stars align) pact with f-star. Article | Follow @JohnCFierce

> Vertex scrambles for quick OK of blockbuster telaprevir app. News

> Tiny Clarus Therapeutics gambles on an $86M IPO. Report

> Galleon Pharma lands $10M for sleep apnea program. Item

> Uphill climb gets even steeper for biotech IPOs. Story

Biotech Research News

> Researchers discovering the mechanics of fat. Article 

> Depression, diabetes go hand-in-hand. Item 

> Tiny spinal implant helps paraplegics exercise. Report

Vaccines News

> Burkina Faso first to receive African meningitis vax. Story 

> Immunovaccine to focus on ovarian cancer. Item 

> Medicare panel backs Provenge. Report 

Manufacturing News

> Judge rules against Baxter in heparin case. Story

> Pharma turning tide against cargo thieves. News

> Counterfeiter gets one year in jail. Item

And Finally... H5N1 bird flu may have fallen off the public radar, but cases show it's still a threat. Report

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.